Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16426482 | 0.89 | KDM4E (0.49) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL16421153 | 0.85 | MEN1 (0.41) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL21105824 | 0.84 | KDM4E (0.43) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL861505 | 0.84 | KDM4E (0.43) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL11956477 | 0.84 | KDM4E (0.43) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL21933196 | 0.84 | CES2 (0.39) | KDM4ETDP1CYP2C19ALDH1A1HTT | |
| SCHEMBL22970115 | 0.82 | MEN1 (0.39) | KDM4EMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL20325163 | 0.81 | KDM4E (0.39) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL24764220 | 0.81 | KDM4E (0.42) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL24756940 | 0.81 | KDM4E (0.41) | KDM4EPOLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | KDM4E 1212/4885TDP1 1050/4885POLB 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.